Last reviewed · How we verify
UGN-104
UGN-104 is a synthetic, small molecule that acts as a prodrug, which is converted into its active metabolite in the bladder.
UGN-104 is a synthetic, small molecule that acts as a prodrug, which is converted into its active metabolite in the bladder. Used for Non-muscle invasive bladder cancer.
At a glance
| Generic name | UGN-104 |
|---|---|
| Also known as | UGN-104 (mitomycin) for pyelocalyceal solution |
| Sponsor | UroGen Pharma Ltd. |
| Drug class | Thymidine analog |
| Target | Thymidine synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The active metabolite of UGN-104 is a thymine analog that intercalates into DNA, thereby inhibiting thymidine synthase and DNA synthesis in cancer cells. This leads to the induction of apoptosis and inhibition of cancer cell proliferation.
Approved indications
- Non-muscle invasive bladder cancer
Common side effects
- Cystitis
Key clinical trials
- A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |